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One of the major goals of neuroscience is to
develop rational and effective treatments for
neurological disorders. Despite technical and
conceptual advances in the neurosciences, there are
many fundamental questions which are still
unanswered. Among the most problematic
neurologic disorders are those associated with the
loss of brain neurons. Neurodegenerative diseases,
congenital disorders, strokes, and penetrating
wounds and injury produce unique patterns of
behavioral symptoms associated with destruction of
specific neuronal populations in the brain and spinal
cord. Our understanding of the pathology and
molecular biology of these disorders has increased;
however, there remains a wide gap between our
understanding of the neural substrates of these
disorders and our ability to prevent or treat them
effectively. With regard to head and spinal cord
injuries specifically, the devastating effects can
happen so swiftly and with such magnitude that it is
important to find treatments which can reduce the
nervous system’s reaction to the injury and promote
full recovery or function.
In the Ninth Annual Symposium on the Neural
Basis of Behavior at the annual meeting of the
Society for Neuroscience in Anaheim, California, on
October 25, 1992, the speakers reviewed and
discussed behavioral and functional effects of
various putative pharmacological therapies for brain
injury and degeneration from basic scientific and
clinical perspectives. The purpose of the symposium
was to present new evidence and avenues of
approach for studying pharmacological strategies
for behavioral restoration following brain damage.
The symposium was organized by Paul R. Sanberg,
University of South Florida and William F. Freed,
National Institute of Mental Health, and
subsequently chaired and introduced by Paul R.
Sanberg. This was followed by an overview of
conceptual and practical issues involved in the
pharmacological treatment of brain injury by Donald
G. Stein, Rutgers University. Dennis M. Feeney,
University of New Mexico, described the effects of
catecholaminergic drugs on functional recovery
from brain injury. Larry Goldstein, Duke University,
described similar effects of noradrenergic drugs in
brain injury patients. Timothy Schallert, University
of Texas at Austin, presented preclinical data in an
assymmetrical injury model in rats demonstrating
that behavioral events are necessary for neuronal
changes to take place. Andrew B. Norman,
University of Cincinnati, discussed the role of fetal
tissue transplants and glutamate receptor
antagonists in influencing recovery in neuro-
degenerative disorders. Tom J. Walsh, Rutgers
University; described antioxidant therapy for
producing behavioral recovery. And finally, C.
Anthony Altar discussed the effects of BDNF as a
therapeutic approach for brain degeneration.
All these investigators have explored a number
of avenues which will lead to further understanding
for possible treatments of brain injury and
neurodegenerative disorders. These included basic
scientific and clinical studies which may all prove
beneficial in increasing the quality of life in the many
patients with neurological disorders. The purpose of
the symposium was to review and emphasize these
contributions especially as related to behavioral
investigations for studying these disorders. The
following peer-reviewed articles in this issue also
highlight these areas and the potential of these novel
psychotherapeutic approaches as treatments for this
important public health problem.
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